Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Summit Therapeu ADR (NQ: SMMT )

8.390 +0.300 (+3.71%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 14, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,863,638
Open 7.960
Bid (Size) 8.360 (30)
Ask (Size) 8.390 (1)
Prev. Close 8.090
Today's Range 7.960 - 8.480
52wk Range 1.520 - 11.25
Shares Outstanding 97,381,774
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Week In Review: Structure Reports Efficacy Of Obesity Drug; Raises $476 Million
Structure Therapeutics announced positive clinical results for its obesity drug, and then raised $476 million via an offering of its ADSs. Meanwhile, Alphamab Oncology announced a deal with ArriVent... 
Via Talk Markets
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga

Performance

YTD
+217.80%
+217.80%
1 Month
+79.08%
+79.08%
3 Month
+76.63%
+76.63%
6 Month
+217.80%
+217.80%
1 Year
+330.26%
+330.26%

More News

Read More
Five Below Posts Weak Q1 Results, Joins Sprinklr, Dorian LPG And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Via Benzinga
Why Summit Therapeutics Stock Is Trading 8% Higher Monday
Via Benzinga
Stericycle, MarineMax, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Monday
Via Benzinga
Summit Raises $200 Million; Also Expands License Territories for Ivonescimab
From Summit Therapeutics Inc.
Via Business Wire
Day Trading During A Slow Holiday Week
Via Talk Markets
Week In Review: MediLink And BioNTech Form $1.8 Billion ADC Partnership
Via Talk Markets
Ivonescimab Manuscript for HARMONi-A Clinical Trial Results Published in JAMA
From Summit Therapeutics Inc.
Via Business Wire
Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for 2L+ EGFRm NSCLC based on HARMONi-A Clinical Trial: Positive Trend Observed in Overall Survival towards Ivonescimab Plus Chemotherapy
From Summit Therapeutics Inc.
Via Business Wire
Why SentinelOne Shares Are Trading Lower By 16%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Summit Therapeutics' Lung Cancer Therapy Ivonescimab Shows Improved Progression-Free Survival Versus Merck's Multi-Billion Keytruda In China Study
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Why Zscaler Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Via InvestorPlace
Marvell Technology Posts Weak Q1 Results, Joins MongoDB, Dell Technologies And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Via Benzinga
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Summit Therapeutics Inc.
Via Business Wire
Ivonescimab Monotherapy Decisively Beats Pembrolizumab Monotherapy Head-to-Head, Achieves Statistically Significant Superiority in PFS in First-Line Treatment of Patients with PD-L1 Positive NSCLC in China
From Summit Therapeutics Inc.
Via Business Wire
Why Applied DNA Sciences Shares Are Trading Lower By Around 68%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Why Summit Therapeutics Stock Is Sinking Today
Via The Motley Fool
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Why NetEase Shares Are Trading Lower? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Why Ross Stores Shares Are Trading Higher By Over 8%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.